PL3019167T3 - Leczenie podwyższonych poziomów eozynofili i/lub bazofili - Google Patents

Leczenie podwyższonych poziomów eozynofili i/lub bazofili

Info

Publication number
PL3019167T3
PL3019167T3 PL14822432T PL14822432T PL3019167T3 PL 3019167 T3 PL3019167 T3 PL 3019167T3 PL 14822432 T PL14822432 T PL 14822432T PL 14822432 T PL14822432 T PL 14822432T PL 3019167 T3 PL3019167 T3 PL 3019167T3
Authority
PL
Poland
Prior art keywords
basophils
eosinophils
treatment
elevated levels
elevated
Prior art date
Application number
PL14822432T
Other languages
English (en)
Inventor
Michael E. Bozik
Gregory HEBRANK
Jr. Thomas Petzinger
Steven Dworetzky
Wildon Farwell
Original Assignee
Knopp Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/966,229 external-priority patent/US9468630B2/en
Application filed by Knopp Biosciences Llc filed Critical Knopp Biosciences Llc
Publication of PL3019167T3 publication Critical patent/PL3019167T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL14822432T 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili PL3019167T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361845944P 2013-07-12 2013-07-12
US201361859158P 2013-07-26 2013-07-26
US201361865118P 2013-08-12 2013-08-12
US13/966,229 US9468630B2 (en) 2013-07-12 2013-08-13 Compositions and methods for treating conditions related to increased eosinophils
USPCT/US2013/054804 2013-08-13
US201461987117P 2014-05-01 2014-05-01
EP14822432.2A EP3019167B1 (en) 2013-07-12 2014-07-11 Treating elevated levels of eosinophils and/or basophils
PCT/US2014/046380 WO2015006708A1 (en) 2013-07-12 2014-07-11 Treating elevated levels of eosinophils and/or basophils

Publications (1)

Publication Number Publication Date
PL3019167T3 true PL3019167T3 (pl) 2021-06-14

Family

ID=52280641

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14822432T PL3019167T3 (pl) 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili
PL21155067.8T PL3838271T3 (pl) 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21155067.8T PL3838271T3 (pl) 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili

Country Status (21)

Country Link
US (6) US10828284B2 (pl)
EP (3) EP3838271B1 (pl)
JP (1) JP6329717B2 (pl)
CN (1) CN105764507B (pl)
AU (1) AU2014287067C1 (pl)
BR (1) BR112016000627B1 (pl)
CA (1) CA2918035C (pl)
CY (1) CY1123914T1 (pl)
DK (2) DK3019167T3 (pl)
ES (2) ES3043076T3 (pl)
FI (1) FI3838271T3 (pl)
HR (2) HRP20251187T1 (pl)
HU (1) HUE054185T2 (pl)
IL (1) IL243508B (pl)
LT (2) LT3838271T (pl)
PL (2) PL3019167T3 (pl)
PT (2) PT3019167T (pl)
RS (2) RS61539B1 (pl)
SI (2) SI3838271T1 (pl)
SM (2) SMT202500364T1 (pl)
WO (1) WO2015006708A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
HRP20251187T1 (hr) 2013-07-12 2025-11-21 Areteia Therapeutics, Inc. Liječenje povišenih razina eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
IT201600077186A1 (it) * 2016-07-22 2018-01-22 Alberto Chiarugi Uso di agente per indurre broncodilatazione
EP3576733A4 (en) * 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
MX2023001140A (es) * 2020-08-05 2023-05-18 Areteia Therapeutics Inc Uso del dexpramipexol para el tratamiento de asma moderado a grave.
WO2023091608A2 (en) * 2021-11-18 2023-05-25 Memorial Sloan-Kettering Cancer Center Methods for treating anti-cancer drug-related skin rashes using benralizumab
WO2025137502A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Osmotic tablets of dexpramipexole and methods of manufacturing and use thereof
WO2025137230A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
US20250352520A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US760704A (en) * 1903-11-14 1904-05-24 Frederick W Saworski Bobbin and spindle connector.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4395859A (en) 1980-06-05 1983-08-02 State Of Illinois, Department Of Transportation Method and apparatus for securing an object to a support structure
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4725272A (en) 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
JPS6155377A (ja) 1984-08-25 1986-03-19 Shimadzu Corp 回転形流体エネルギ変換機
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4645502A (en) 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
EP0249343B1 (en) 1986-06-13 1992-01-08 Alza Corporation Moisture activation of transdermal drug delivery system
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5071656A (en) 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
EP0387751B1 (en) 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
US5591454A (en) 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5024843A (en) 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
WO1993024834A1 (en) 1992-05-29 1993-12-09 The Rockefeller University Method and product for the sequence determination of peptides using a mass spectrometer
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
EP1347493A3 (en) 1993-05-28 2005-11-23 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
EE04177B1 (et) 1995-10-26 2003-12-15 Sanofi 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9705428D0 (en) 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US5804215A (en) 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US5883995A (en) 1997-05-20 1999-03-16 Adc Telecommunications, Inc. Fiber connector and adapter
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1018144A1 (en) 1997-09-23 2000-07-12 Ciphergen Biosystems, Inc. Secondary ion generator detector for time-of-flight mass spectrometry
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
WO1999051097A1 (en) 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
AU5314900A (en) 1999-06-04 2000-12-28 Elan Pharma International Limited Compositions and methods for inhibiting cell death
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
US6480820B1 (en) 1999-09-20 2002-11-12 Advanced Cochlear Systems, Inc. Method of processing auditory data
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
US6750235B1 (en) 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
TWI292316B (en) 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
EP1257560A4 (en) 2000-02-01 2003-10-01 Human Genome Sciences Inc BCL-2 SIMILAR POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
EP2330219A3 (en) 2000-04-14 2011-11-23 Metabolon, Inc. Method for drug discovery, disease treatment and diagnosis using metabolomics
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
AU7887501A (en) 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US6618138B2 (en) 2000-10-12 2003-09-09 Jed Khoury Scanning fluorescent systems for various diagnostic
CA2429327A1 (en) 2000-11-16 2003-04-17 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
ATE424194T1 (de) 2001-04-09 2009-03-15 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
JP4511169B2 (ja) 2001-06-12 2010-07-28 エルジー エレクトロニクス インコーポレイティド 全自動洗濯機及びその制御方法
US20030013120A1 (en) 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
DE10137082A1 (de) 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2351303T3 (es) 2001-12-11 2011-02-02 University Of Virginia Patent Foundation Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
MY139056A (en) 2001-12-28 2009-08-28 Ab Enzymes Gmbh Microbially-expressed thermotolerant phytase for animal feed
EP1467712B2 (en) 2002-01-16 2011-08-31 Boehringer Ingelheim Pharma GmbH & Co. KG Method of producing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
US20030166696A1 (en) 2002-01-24 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexole for the treatment of HIV dementia
RU24834U1 (ru) 2002-02-14 2002-08-27 Закрытое акционерное общество "ЭКО-АТОМ" Устройство для многостадийной обработки воды
JP2005525345A (ja) 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
DE10213571A1 (de) 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
WO2003087834A2 (en) 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
AU2003237379A1 (en) 2002-06-10 2003-12-22 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
KR100505260B1 (ko) 2002-06-28 2005-07-29 노건웅 알레르기를 유발하는 특정 물질에 대한 내성 유도 방법,내성 유도용 키트 및 이들을 이용한 내성 획득 방법
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
GB0221513D0 (en) 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
WO2004026246A2 (en) 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US6904663B2 (en) 2002-11-04 2005-06-14 Taylor Made Golf Company, Inc. Method for manufacturing a golf club face
GB2394951A (en) 2002-11-04 2004-05-12 Cipla Ltd One pot synthesis of 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole
US20050202093A1 (en) 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
UA79182C2 (en) 2002-12-13 2007-05-25 Basf Ag Method for the production of benzophenones
JP2006516549A (ja) 2002-12-23 2006-07-06 メルク フロスト カナダ アンド カンパニー パーキンソン病の治療用医薬組成物及び治療方法
DE602004031512D1 (de) 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005010011A2 (en) 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
DE10333393A1 (de) 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
US7365086B2 (en) 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050053649A1 (en) 2003-09-08 2005-03-10 Anne-Marie Chalmers Medication delivery device
ITRM20030459A1 (it) 2003-10-07 2005-04-08 Sipa Societa Industrializzazione P Rogettazione A Dispositivo e processo di estrazione di oggetti in materia plastica.
EP1685259A4 (en) 2003-10-23 2007-12-12 Univ Pittsburgh BIOMARKER FOR AMYOTROPHE LATERAL SCLEROSIS
DE602005025988D1 (de) 2004-03-19 2011-03-03 Dipharma Francis Srl Zwischenprodukte für die herstellung von pramipexol
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US7539203B2 (en) 2004-05-26 2009-05-26 Intel Corporation Multiple channel flow control with first-in-first-out (FIFO) read/write random access memory (RAM)
JP2008502609A (ja) 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
WO2006012277A2 (en) 2004-06-30 2006-02-02 Amr Technology, Inc. Biocatalytic process for preparing enantiomerically enriched pramipexole
EP1773793A2 (en) 2004-07-03 2007-04-18 Merck Generics (UK) Limited Process for the preparation of pramipexole by chiral chromatography
DE102004034987A1 (de) 2004-07-16 2006-02-02 Carl Zeiss Jena Gmbh Lichtrastermikroskop und Verwendung
NZ553645A (en) 2004-08-13 2010-09-30 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553561A (en) 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004044578A1 (de) 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
US20060069263A1 (en) 2004-09-30 2006-03-30 Irina Gribun Process for the reduction of (S)-2-amino-6-propionamido-4,5,6,7-tetrahydrobenzo-thiazole
JP2006143708A (ja) 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
WO2006043532A1 (ja) 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
HRP20140212T1 (hr) 2004-11-05 2014-04-11 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
WO2006071469A2 (en) 2004-12-02 2006-07-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis
WO2006060799A2 (en) 2004-12-02 2006-06-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis
WO2006070406A1 (en) 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
DE112005003227T5 (de) 2004-12-30 2007-11-15 Chemagis Ltd. Neues Verfahren zur Herstellung von Pramipexol und dem Gemisch seiner optischen Isomeren durch Reduktion mit Natriumtriacetoxyborhydrid
JP2008527002A (ja) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2006113681A2 (en) 2005-04-15 2006-10-26 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
ZA200708857B (en) 2005-04-22 2009-01-28 Genentech Inc Method for treating dementia or alzheimer's disease with a CD30 antibody
US20060286167A1 (en) 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
ES2264378B1 (es) 2005-05-09 2007-11-01 Ragactives, S.L. Procedimiento para la resolucion de 2-amino-6propilamino-4,5,6,7-tetrahidrobenzotiazol y compuestos intermedios.
WO2006126948A1 (en) 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
ES2334061T3 (es) 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
WO2007046347A1 (ja) 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
JP2009511618A (ja) 2005-10-18 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
PL378587A1 (pl) 2005-12-29 2007-07-09 Instytut Farmaceutyczny Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007121188A2 (en) 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2497472A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions
PL2026803T3 (pl) 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
KR20090045943A (ko) 2006-08-24 2009-05-08 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 저장 안정성이 높은 프라미펙솔 디하이드로클로라이드 정제의 제조방법
US20080081041A1 (en) 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
WO2008041240A1 (en) 2006-10-03 2008-04-10 Cadila Healthcare Limited Process for preparing (s)-pramipexole and its intermediates
TW200829241A (en) 2006-10-30 2008-07-16 Boehringer Ingelheim Int Treatment of parkinson's disease
RU2491068C2 (ru) 2006-12-14 2013-08-27 Нопп Ньюросайенсиз, Инк. Композиции и способы применения (r)-прамипексола
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101641096A (zh) * 2006-12-14 2010-02-03 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
WO2008104847A2 (en) 2007-02-26 2008-09-04 Wockhardt Research Centre Processes for the preparation of pramipexole and salts thereof
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
AU2008224869A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
WO2008140051A1 (ja) 2007-05-11 2008-11-20 Santen Pharmaceutical Co., Ltd. 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
TWM367342U (en) 2009-05-01 2009-10-21 Advanced Connectek Inc Fiber optics adapter
US8408815B2 (en) 2009-06-18 2013-04-02 Senko Advanced Components, Inc. Optical fiber connector and adapter
AU2010262970A1 (en) 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2011005645A1 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Polymorph of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]
AU2010281524A1 (en) * 2009-08-06 2012-02-23 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
US20130079526A1 (en) 2010-03-03 2013-03-28 Knopp Neurosciences Inc. Synthesis of Chirally Purified Substituted Benzothiazole Diamines
US20130058072A1 (en) 2010-03-31 2013-03-07 Intexs Corporation Light-source device
US20130273557A1 (en) 2010-05-26 2013-10-17 Valentin Gribkoff Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits
WO2012075473A1 (en) 2010-12-03 2012-06-07 Euthymic Bioscience, Inc. Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US20130059801A1 (en) 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Fatty acid amides, compositions and methods of use
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013096870A1 (en) 2011-12-22 2013-06-27 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014134569A1 (en) 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
HRP20251187T1 (hr) 2013-07-12 2025-11-21 Areteia Therapeutics, Inc. Liječenje povišenih razina eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
JP6115377B2 (ja) 2013-07-24 2017-04-19 Jsr株式会社 樹脂組成物及びレジストパターン形成方法
DE102013108610A1 (de) 2013-08-06 2015-02-12 Rogers Germany Gmbh Metall-Keramik-Substrat sowie Verfahren zum Herstellen eines Metall-Keramik-Substrates
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
WO2015061777A2 (en) 2013-10-25 2015-04-30 Oral Alpan Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist

Also Published As

Publication number Publication date
EP3019167B1 (en) 2021-02-17
PT3019167T (pt) 2021-03-04
US10383857B2 (en) 2019-08-20
US20210267949A1 (en) 2021-09-02
HRP20210368T1 (hr) 2021-04-16
CA2918035C (en) 2023-01-03
US11612589B2 (en) 2023-03-28
CN105764507B (zh) 2019-07-19
US20230277509A1 (en) 2023-09-07
JP6329717B2 (ja) 2018-05-23
US11026928B2 (en) 2021-06-08
EP3019167A1 (en) 2016-05-18
EP3838271B1 (en) 2025-09-03
WO2015006708A1 (en) 2015-01-15
CN105764507A (zh) 2016-07-13
SMT202500364T1 (it) 2025-11-10
SI3838271T1 (sl) 2025-12-31
CA2918035A1 (en) 2015-01-15
ES2858500T3 (es) 2021-09-30
DK3019167T3 (da) 2021-03-15
LT3019167T (lt) 2021-03-25
PT3838271T (pt) 2025-09-23
HRP20251187T1 (hr) 2025-11-21
RS67279B1 (sr) 2025-10-31
LT3838271T (lt) 2025-11-10
BR112016000627A2 (pl) 2017-07-25
IL243508B (en) 2019-02-28
US20180228777A1 (en) 2018-08-16
EP3838271A1 (en) 2021-06-23
AU2014287067B2 (en) 2019-04-18
RS61539B1 (sr) 2021-04-29
EP3019167A4 (en) 2017-01-18
PL3838271T3 (pl) 2025-12-15
SI3019167T1 (sl) 2021-04-30
AU2014287067C1 (en) 2019-07-25
JP2016523981A (ja) 2016-08-12
US12138249B2 (en) 2024-11-12
US20180271839A1 (en) 2018-09-27
DK3838271T3 (da) 2025-09-29
FI3838271T3 (fi) 2025-10-12
US20250099437A1 (en) 2025-03-27
EP4578509A2 (en) 2025-07-02
US10828284B2 (en) 2020-11-10
CY1123914T1 (el) 2022-05-27
ES3043076T3 (en) 2025-11-24
BR112016000627B1 (pt) 2022-02-08
AU2014287067A1 (en) 2016-02-04
HUE054185T2 (hu) 2021-08-30
EP4578509A3 (en) 2025-11-19
SMT202100119T1 (it) 2021-05-07
US20160158205A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
PL3019167T3 (pl) Leczenie podwyższonych poziomów eozynofili i/lub bazofili
IL283173A (en) Human igg1 fc region variants and uses thereof
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
HRP20190528T1 (hr) PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
CL2015002146A1 (es) Composiciones y procedimientos para tratar heridas superficiales
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
BR112016008387A2 (pt) Conjunto de absorvente descartável, e, artigo absorvente
EP3325100A4 (en) COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
PL2948137T3 (pl) Sposoby leczenia zwłóknienia i nowotworów
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
DE112013006389A5 (de) Aktuator und Verwendung eines Aktuators
PL2976089T3 (pl) Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia
FR3007291B1 (fr) Composition cicatrisante et utlisation
HRP20190279T1 (hr) Liječenje ovisnosti i poremećaja nagona pomoću pde7 inhibitora
HRP20181181T1 (hr) Postupak obrade i liječenja lišmenioze uporabom feksinidazola
TH1401007179A (th) องค์ประกอบและการใช้ของมันเพื่อป้องกันและรักษาตับอักเสบบี
FR3005395B1 (fr) Lits de roulis et de tangage
TH1301006828B (th) วิธีการดัดแปลงผิวและอุปกรณ์ดัดแปลงผิว
TH1401007376A (th) ไดอะซาสไปโรไซโคลแอลเคนและอะซาสไปโรไซโคลแอลเคนชนิดใหม่